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Abstract
The substitution of deuterium, an isotope of hydrogen containing one proton and one
neutron, for a hydrogen has far reaching effects on the behavior of the compound. Scientists have
been utilizing the effects of deuterium since 19611. The primary purpose for deuterium has been
concentrated in the development of internal standards for NMR and mass spectrometers, due to
their relative ‘silence’ in these studies, allowing scientists to elucidate mechanisms and trace a
compound's movement throughout the body. However, recently, in addition to the use of
deuterium as a standard, it has been added to developing or previously created pharmaceutical
compounds with the intent to stabilize the drug. This stabilization can take many forms,
including decreasing the rate of metabolic breakdown, decreasing enantiomeric switching, and,
in some cases, decreasing toxicity. With this more widespread application, a resurgence of
studies have been completed to develop new methods of deuterating a wide variety of molecules,
with a focus on common functional groups found within pharmaceutical compounds and mild
reaction conditions.

Pharmaceutical Applications
General Effects
Pharmaceuticals are generally analyzed according to several different features:
absorption, distribution, metabolism, and excretion (ADME)2 through isotopic labeling. The
heavier than normal element allows scientists to track the drug as it moves throughout the body.
However, deuterium has an additional effect on the compound known as the kinetic isotope
effect (KIE)2,3,. Deuterium changes the pharmacokinetics of the compound, or how the drug
moves throughout the body2. Though the difference in bond enthalpies of C-D and C-H is just
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1.8 kJ*mol-1 4, the addition of deuterium decreases the rate of metabolism3. This allows for a
decrease in both the dosage and frequency of dosage which in turn lessens the negative side
effects5.
Deuterium can also be utilized in pharmaceutical compounds in order to stabilize
stereocenters5. The addition of deuterium on a chiral center allows the emergence of one, more
common, enantiomer6. This, in turn, allows for the development of a medicine with more
beneficial effects. Moreover, this stabilization is important as some compounds have a toxic
enantiomer and isolation of the beneficial enantiomer was previously impossible due to the chiral
environment of the body. While the deuterated compounds may not be entirely stable, it is up to
five times more stable than its deuterium-lacking counterpart5.

Deuterium Containing Drugs in Development (or Approved)
A drug in clinical development goes through four distinct phases. The first phase involves
15-50 patients and aims to determine whether or not a drug is safe; it is given increasingly large
doses to determine the magnitude of negative side effects. Phase II involves a larger sample
study and begins to determine the effectiveness of a drug, whether or not it will produce the
desired outcome. Often, this stage also involves testing the compatibility of the drug in
development to other medications used to treat the disease. In the third phase, the developing
drug is compared to the current standard of care drug. In this phase, participants are chosen
randomly and are not told whether or not the drug that they are receiving is experimental or the
standard. Moreover, each patient is watched carefully for side effects. This last phase tests the
drug after it is approved by the FDA in several thousands of patients and studies both long and
short term effects. This stage can also involve testing for compatibility with other drugs7.
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Figure 1: A pie chart detailing the distribution of the phases of development of the deuterated
drugs. The raw data can be found in Appendix A and was simplified so each drug is only
represented once.
The first deuterated drug that was approved by the Food and Drug Administration (FDA)
was Austedo, deutetrabenazine, deuterated benzoquinoline, or d6-tetrabenazine, developed by
Teva Pharmaceuticals5,8. It should be noted that in addition to this drug being approved by the
FDA, it received a patent as a New Molecular Entity (NME)9. This drug is used to treat chorea
(tremors) caused by Huntington's disease which are caused by reducing dopamine and serotonin
production8. As previously mentioned, the main effect of deuterium in this compound is the
decrease in the metabolic breakdown by 69-87%9. This allows the drug to be administered only
twice a day leading to a decrease in negative side effects such as sleepiness, depression, and
anxiety8. Currently, there are twenty different pharmaceutical compounds in various stages of
testing that contain deuterium5. Of these, sixteen compounds are deuterium containing analogs to
already approved and administered drugs, two are deuterated forms of nutritional compounds,
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and two do not have a non-deuterated counterpart, meaning deuterium was utilized from the
beginning stages of development5.

Figure 2: A pie chart detailing the different effects that the addition of deuterium has on already
known drugs.
Aldehyde Oxidase and Metabolism
A study on the development of a heroin “vaccine” provides further evidence that the body
can differentiate between hydrogen and deuterium30. This vaccine is a heroin haptinn that would
elicit an immune response from the body which in turn would prevent heroin and heroin
metabolites from entering the brain. Heroin breaks down first into 6-monoacetylmorphine (6AM)
and then morphine; it is morphine that causes the negative side effects of heroin. The deuterated
vaccine for heroin bonded more closely to heroin than the non-deuterated vaccine. The reason
for this tighter bonding is not fully known and most likely has to do with “different T-cell
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dependent B-cell receptor activation populations”. This difference however clearly indicates that
the immune system can differentiate between deuterium and hydrogen. Furthermore, the
deuterated vaccine also allowed for an increase in 6AM as the breakdown was no longer subject
to P450; the deuterated compound slowed the rate of metabolism allowing for a decrease in the
metabolite causing undesired effects30.
The addition of deuterium to slow the metabolism of a drug was utilized in the
development of HC-114428. The phosphorylation and activation of Vascular endothelial growth
factor receptors (VEGFR) leads to the creation of new tumors. Tivozanib is a VEFGR inhibitor
with a longer progression-free survival. However, there was a large increase in both hypertension
(34% to 44%) and dysphonia (5% to 21%) compared to sorafenib, a less effective VEFGR
inhibitor. The deuterated analog of Tivozanib (HC-1144) was as effective in vitro as Tivozanib
itself. HC-1144 was synthesized through the deuteration of an early reactant and had a 69%
yield. HC-1144 had a larger half-life, a larger max concentration (Cmax, meaning smaller doses
could be given), a 1.5 times larger AUC (an integral of the change in concentration over time,
meaning that the compound stayed in the body for a longer period of time) and a similar peak
time (meaning the release of the drug was not further delayed) 28.

Stabilization of Chiral Center
The isolation of the beneficial enantiomer (eutomer) from the undesired enantiomer
(distomer) first arose around the 1990s, allowing for the creation of drugs such as Nexium,
Lexapro, Lunesta, and Xopenex 31. However, some compounds, such as those with hydrogen at
the chiral center, could not be isolated due to enantiomeric switching in vivo. This switching
can be stabilized through deuterium labeling. For example, (S)-D lenalidomide is ten times
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more potent than racemic lenalidomide and (-)-D avadomide was 20 times more potent than its
racemic mixture 31. Furthermore, the deuterated analog had a reduction in degradation rate as
well. The addition of deuterium at the chiral center pioglitazone, creating the drug DRX-065
which is used to treat diabetes, allowed for the a reduction in PPARɣ agonist activity which
causes weight gain, edema (swelling), and bone fracture as it is caused solely by the S
enantiomer 10. However, it should be noted that deuteration did not affect the stability of
inolitazone 31.

Intellectual Property Laws
While deuterated compounds do possess beneficial side effects, there is some controversy
surrounding these drugs due to intellectual property laws5. Determination of whether or not a
deuterated form of a pre-existing compound can be considered a new compound, and thus be
eligible for a new patent, is done on a case by case basis. Some believe that scientists are using
deuterated forms of their compounds as merely a way to extend their patent without fully
developing a new product5.
However, this is not to say that the intention of all scientists behind the development of
deuterated drugs are less than pure. At least two drugs containing deuterium are currently in
development that do not have an analog. This suggests that deuterium is becoming more
prominent in methods of drug design. Furthermore, deutetrabenazine was approved as a NME,
rather than as an extension of tetrabenazine, suggesting that sometimes the KIE can be large
enough to have a significant, patentable effect10. Moreover, the process of deuterating a drug is
complex. One would have to determine exactly which hydrogen atoms should be exchanged and
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then study the effects of the drug. This study is complicated by the fact that sometimes while
drugs are beneficial in vitro they are not in vivo5.
The issue of patentability has large monetary importance, increasing its importance. The
intellectual property rights for a deuterated version of lenalidomide, with the addition of
deuterium decreasing the rate of racemization, was sold from Deuteria Pharmaceuticals to
Celegene for 42 billion dollars11. This sale occurred before the drug was fully developed. On a
much larger scale, Teva Pharmaceuticals paid 3.5 billion dollars to acquire Auspex, the company
reasonable for the development of Austedo.
Patentability would become even more difficult if the rights to the deuterated drug were
owned by a different company than the one that sells the non-deuterated drug. Because there can
never be one-hundred percent deuterium incorporation, some of the deuterated drug would be
sold with its deuterium-lacking counterpart—a complication that could lead to lawsuits. To
counteract this possibility, many companies, such as Celegene, are purchasing or patenting any
deuterated analogs.

Toxicity and Cost Concerns
Deuterium does not only have positive effects on the compound, however. In some
instances, the metabolites of the deuterated compound are toxic, while the metabolites of the
undeuterated compound are not5. It should be noted that generally, this is not the case and
deuterium is relatively non-toxic. Deuterium would need to be present in 20% of a humans total
body water before it reached toxic levels and even then this toxicity is reversible 9, 10. However,
in some instances, such as with JNJ-38877605 and HC-1119, the toxicity could decrease12. In
this way, deuterium could be used to ‘save’ already developed drugs that proved too toxic to pass
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phase one clinical trials. Therefore, it is essential to study the toxicity at all stages when
developing new drugs, even if the only new aspect is the addition of deuterium.
Another concern is the cost of deuteration. While strides have been made in the field,
many reactions still involve precious metals such as gold or deuterated solvents, both of which
increase the cost of production. Though this cost could be partially mitigated by the decrease in
dosage size and the relatively small amount of deuterium needed, it still may remain too high for
some. Due to cost and selectivity issues of deuteration as well as limited KIE, Cargnin et. al.
suggests that less than 10% of the drugs currently on the market are good candidates for
deuteration12. Nevertheless, an increasing number of drugs containing deuterium are produced,
with several sources comparing deuterium's potential to that of fluorine.

Comparison with Fluorine
Fluorine, beginning in the 1970s, began to be added to more drugs for stability. While
originally fluorine was only in 2% of drugs, it is now in around 50%5. Several articles draw the
parallel between deuterium labeling and the addition of a fluorine group 12,5. Furthermore, the
addition of a deuterium atom can, in some cases, be more beneficial than the addition of fluorine.
Most notable this occurs when changes in electronegativity and steric hindrance cannot be
tolerated. One example of this is the recent study on how to best improve Celecoxib.
Celecoxib is an anti-inflammatory, pain relieving, antipyretic drug that belongs to a class
of cyclooxygenase-2 (COX-2) inhibitors. These drugs currently lack a radiotracer as current
tracers lack either specific binding, metabolic stability, or ability to demonstrate COX-2 binding
in vivo. This study focuses on increasing the metabolic stability of methylsulfonyl-substituted
celecoxib through the addition of deuterium or fluorine. Deuterium was added through the
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reduction of an intermediate with LiAlD4, rather than LiAlH4. Deuterium was found to not
change the COX-2 inhibitory potency but lengthening the fluoroethyl chain decreased both the
inhibitory potency and selectivity. While the two variations had similar pharmacokinetic
patterns, the deuterium substituted variation was more intact after 60 minutes (52% remaining vs
28% remaining). Deuteration enhances metabolic stability both in vitro and in vivo the most; it
has a greater positive effect than the addition of fluorine29.
Deuterium was also chosen over fluorine in the development of JNJ-38877605 12. While
fluorine was the first instinct of the developers to stabilize this drug, it could not be used as it
would affect the ability of the compound to bond with the residue of kinase as it needs to do 12.

A Comprehensive List of Deuterated Drugs?
Currently, there are twenty different pharmaceutical compounds in various stages of
testing that contain deuterium5. Of these, sixteen compounds are deuterium containing analogs to
already approved and administered drugs, two are deuterated forms of nutritional compounds,
and two do not have a non-deuterated counterpart, meaning deuterium was utilized from the
beginning stages of development5.
A full list of drugs currently in development and accessible through a search on
clincialtrials.gov can be found in Appendix A. However, it should be noted that this list is not
fully comprehensive as some individual companies advertise the development of deuterium
containing drugs that do not appear in the aforementioned database. Furthermore, many
companies are reluctant to advertise the composition of drugs under development. In May of
2015 when Teva purchased Auspex it was estimated that over 60 deuterated drug candidates
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were being studied11. Currently many companies, including Pfzier, Teva, Concert, Avanir, and
DeuteRx are all researching, or at least patenting, deuterated analogs of drugs in development.

Methods of Deuterium Labeling
Using Nanoparticles and Nanosheets
A number of modern reactions use either nanosheets or nanoparticles, though not
necessarily of the same element. However, while multiple elements can be used to catalyze these
reactions, one common element utilized is cadmium 13,14,15. Cadmium selenide is used in
experiments due to several of its electrochemical properties, such as its bandgap which allows it
to absorb solar energy and its conduction band edge which allows it to reduce water, which lends
itself toward single electron transfer (SET) reactions as it forms D+ ions, which later become
deuterium radicals.15. When CdSe is developed in porous nanosheets, more catalytic sites
become available to the substrate, allowing for more reactions to occur in the same span of
time14,15. Nanowire cadmium sulfide is used for much of the same reasons13.

Figure 3: A reaction scheme for photocatalytic deuterium labeling with CdSe nanosheets15
While some articles found good deuterium incorporation with any halogen13,14, it was
determined that due to both bond enthalpies and reduction potentials, the best results occur when
iodine is used15. Because of the mild reaction conditions, sensitive groups such as cyan, ester,
amaino, hydroxyl, aldehyde, and ketones were not affected15. This marks a significant
improvement over other halogen/deuterium exchanges which commonly use strong bases and
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therefore lack the same degree of flexibility. Though pharmaceutical compounds were not
directly synthesized using this technique, it remains an important step in the synthesis of
deuterated pharmaceutical compounds. Deuterated intermediates that would otherwise remain
inaccessible due to their fragility, such as alkynes, boric acid, and alkene-containing compounds,
can undergo Suzuki coupling or bond insertion in order to form desired products15. An
intermediate for deuterated nicotinic acid, an anti-hypercholesterolemia drug, was synthesized
through this technique before undergoing further ester hydrolysis15.
Palladium, Pd, is another element that, when in nanosheets, is used for reactions in which
an aryl chloride is replaced with a deuterium atom16. Palladium serves as the catalyst to both
activate the C-Cl bond and to replace the chloride atom with a deuterium atom16. Furthermore,
the nanosheet structure of this reagent allows it to collect the electrons released when the
deuterium source, in this case D2O, breaks down as well as regenerate the sacrificial agent16.

Figure 4: A reaction scheme for the replacement of a chloride atom with a deuterium atom
through the use of a palladium nanosheet 16.
Ruthenium is one of nanocatalysts that has been used for the longest period of time in the
field of deuterium labeling and in a way, paved the way for the aforementioned elements17.
Ruthenium, similarly to palladium, activates the CH bond, allowing the rest of the reaction to
occur17. As this step is the rate determining step, it is important to note that the nanoparticle
nature of the ruthenium atoms decrease the activation energy17. Therefore, while ruthenium is the
catalyst, the innovation of using a nanocluster allows the reaction to proceed faster and with less
energy. Ruthenium nanoparticles, along with D2O, were able to deuterate the α position of the
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nitrogen atom of an amine through the activation of a C(sp3)-H bond. This reaction occurred
enantiospecifically for amino acids with aliphatic, amide, and nitrogen containing side chains17.
Molecules containing multiple good ruthenium coordination units, such as carboxylic acids,
amines, and aromatic rings, had a lower deuterium incorporation due to decrease in flexibility of
the molecule. Notably, these reaction conditions were able to selectively deuterate the Cα carbon
atom of the N-terminal group amino acid of several peptides—a modification of interest in the
field of drug development.

Figure 5: A reaction scheme for a HAT reaction using ruthenium nanoparticle as a catalyst17.

Radical Pathways
The palladium nanosheet previously mentioned has a radical pathway. Palladium works
with the photocatalyst which is, in this reaction, crystalline polymeric carbon nitrides (CPCN)16.
While the CPCN creates the radical deuterium, the palladium nanosheet traps the radical that
causes the HAT to occur16.
Cadmium sulfide, or CdS, has a slightly different radical pathway. It works with gold to
deuterate aryl halides13. The gold releases an electron which is then transferred to first the CdS
nanowire and then the aryl halide13. The halide then falls off of the aryl halide anion leaving an
aryl radical, which is then deuterated by D2O13.
Another radical pathway occurs in the development of deuterated silanes. In this reaction,
the catalyst, 4CzIPN, becomes a radical18. This radical is then quenched by HAT through SET to
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make a thiyl radical18. It is this thiyl radical that both regenerates the photocatalyst and forms the
silane radical18. Once the silane is a radical, it can rob the deuterated thiol of its deuterium atom
and become deuterated18.

Figure 6: A reaction scheme for the deuteration of silanes through the use of the photocatalyst
CzIPN18.
A very similar mechanism occurs with iridium, Ir, as the photocatalyst. However, in this
reaction, amines, rather than silanes, are deuterated and several intermediate steps are eliminated.
This reaction starts when the ‘excited’ iridium atom oxidizes an amine, forming an amino radical
at the alpha position19. This amino radical is then deuterated with the same deuterium donor as
the previous reaction, deuterated thiol.

Figure 7: A reaction scheme for the deuteration of α-amines through the use of the photocatalyst
iridium19.
Some mechanisms, unlike those previously mentioned, do not require a catalyst. Instead,
light can immediately activate a bond, such as the S-N bond in arylazo sulfones, forming an aryl
radical20. The weakest CH bond on the ring then undergoes HAT with either deuterated
isopropanol or deuterated THF as the deuterium donor20.
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Figure 8: A reaction scheme for an arylazo sulfane undergoing deuteration without the use of a
photocatalyst20.
Though there are many different individual radical pathways, most follow a similar
pattern. First, the substrate must be radicalized, though this may occur through an
intermediate16,18, due to a photocatalyst 13,16,18,19, or independently20. The substrate then becomes
quenched with the addition of a deuterium atom with the donor changing depending on the
reaction. In some cases, this reaction can be nearly infinite18 while most others are limited by the
amount of reagent.

Photocatalytic Reactions
Due to the current interest and demand for green chemistry, a number of reactions
involving both visible and UV light have been researched 13-16,18-21. These reactions benefit from
conditions that are less harsh, as many do not require strong acids or bases, though some21 still
do. This lack of strong acids generally leads to a higher tolerance of functional groups.
Moreover, it allows for the development of deuterated pharmaceutical compounds, many of
which are not tolerant to extremely basic or extremely acidic solutions. However, these benefits
do not imply that there are no issues with photocatalytic reactions.
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Though much research has been done regarding photoredox reactions22, the best
photocatalyst is still debated. While some, such as gold, allow for a greater separation of charge
and absorption of light in the visible spectrum13 and may have a high quality, others are a
significantly less expensive 18,21 but sacrifice some functional group tolerance and variability.
Still others do not require a photocatalyst20 but only work on one type of molecule. Within the
community, however, it is noted that the photocatalyst CdSe porous nanosheets 14,15 marked a
significant turning point in the ability to label compounds.
A study completed by Kuang et. al. focuses on the direct H/D exchange between D2O
(used at 50 equiv) and molecules containing either formyl C-H or hydriodic C(sp3)-H bonds
using tetra-n-butylammonium decatungstate (TBADT)(2%mol) and 2,4,6-triisopropyl
benzenethiol(10% mol) as HAT photocatalysts25. The direct H/D is preferred because while
halogen/deuterium exchange and reductive deuteration both require precursors, H/D exchange
can be done directly on the compound of interest. The average reaction time was 4-8 hours
under 390nm light, though some substrates, such as the hydric C(sp3)-H bonds that occurred in
the same molecule as an aldehyde group and 4-acetoxybenzaldehyde required either a longer
reaction time (48hr) or higher energy light (365nm).

Figure 9: A reaction scheme for the deuteration of aldehydes through the addition of the
photocatalyst TBADT25.
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Aromatic aldehydes, aldehyde with an electron withdrawing group (ie halides,
trifluoromethyl, cyanide, boronate ester), and aldehydes with electron donating substituents (ie
amides, phenols, ethers) were all able to be deuterated with no lower than 89% deuterium
incorporation. These reaction conditions also allow for selective deuteration for if the reaction
continued for 48hours, the secondary groups (α-oxy,α-thioxy, benzylic C(sp3)-H bonds) could
be deuterated as well. The more hydridic C-H bonds underwent deuteration to a greater extent.
Those molecules with hydridic C(sp3)-H bonds without an aldehyde could be selectively
deuterated as well. However, for these substrates, more TBADT was necessary.
Several pharmaceutical compounds could be deuterated using this method including
ibuprofen, gemfibrozil, heterocyclic drugs (fomepizole, edaravone, pirfenidone) at only the
benzylic C-H bonds, mexiletine, and chloroxylenol. Notably, drugs in the adamantane family
(amantadine, memantine) were deuterated with more than 5 deuterium atoms per molecule and
less than 0.1% unlabeled molecule remaining, allowing them to be used as internal standards in
ADME-Tox biostudies. Several precursors for drugs were also deuterated. However, the
deuteration mainly occurred at the benzylic position, rather than all of the required positions
(missing phenyl methoxy groups and α-carbonyl).

Figure 10: Structures and percent incorporation of deuterium for drugs in the
adamantane family through the use of the TBADT catalyst25.
This reaction proceeds through a radical pathway. A carbon radical is generated through
HAT between the substrate and photo-excited TBADT. The deuterated thiol is made due to the
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presence of excessive D2O. The carbon radical then reacts with the deuterated thiol to make the
deuterated product and a thiyl radical. The thiyl radical interacts with [W10O32]5-H+ to remake
TBADT and deuterated thiol25.
For the deuteration of aldehydes, Garg et. al. focused on using N-heterocyclic carbenes
(NHC). The NHC condensed on the aldehyde forming a Breslow intermediate, which then
underwent deuteration, forming the desired product26. Different catalysts were necessary for
varying aldehydes with varying functional groups. Aryl aldehydes were deuterated using an
imidazolium catalyst, while enal aldehydes used triazolium catalysts26.

Figure 11: A reaction scheme for the deuteration of aldehydes through the addition of NHC26.

Deuterating Pharmaceutical Compounds (miscellaneous)
Deuterating sites that are metabolized is an effective method to slow the deterioration of
a compound. "Metabolism occurs on pyridines and diazines by molybdenum-containing
enzymes such as aldehyde oxidases (AOs)"27. Currently, the drug VX-984, involving a
deuteration that slows this AO metabolism, is in development. Koniarczyk et. al. developed a
method for deuterating pyridines and diazines by first transforming them into phosphonium salts
and then reacting these salts with D2O and K2CO327. This reaction allows for the hydrogen at
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carbon position 4 to be deuterated with high regioselectivity. This is in contrast to several other
methods, including one discovered by Chirk, that for the same compound (loratadine)
deuterated at positions 2 and 3. When this position is blocked the compound is deuterated at
position 2. Pyridines with 3,5-substituents are deuterated with complete regioselectivity, even
when this substituent is a halogen.

Figure 12: The selective deuteration at position 4, the selective deuteration at position 2 when
positive 4 is blocked, and the selective deuteration with 3,5 substituents through the
transformation into salts and then deuteration with K2Co327.
Around 50% of the top-selling pharmaceuticals contain N-alkyl amine groups23.
Recently, a photoredox method was discovered resulting in the deuteration of 𝛼𝛼 bonds. However,
a method for the deuteration of 𝛽𝛽C-H bonds is slightly more complicated due to their increased
stability. Chang et. al. discusses an acid-base reaction containing acetone-d6 as a deuterium

source, B(C6F5)3 as a catalyst, and a reaction temperature of 150℃. The product was then
filtered through silica gel chromatography. Cyano, ester, amide, and ketone N-alkylaines all gave
deuterium products in a yield >95% 23. Moreover, this reaction was more efficient when the
substrate had a hindering group. Some pharmaceutical compounds that were effectively
deuterated include piperidine, 1,4-diazepane, piperazine, thiophene, indanone, benzodioxole,
benzothiophene, benzimidazole, clopidogrel, prasugrel, and doneprezil23.
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Figure 13: A proposed reaction scheme for the deuteration of the β-CH bonds of amines through
the addition of the catalyst B(C6F5)323.
The same catalyst, utilized by Chang et. al. could be used to deuterated carbonyls at
temperatures ranging from 60 to 100℃ (with a higher temperature leading to higher levels of
deuterium incorporation)24. Both acyclic and cyclic bioactive ketones were deuterated, along
with compounds containing methoxy theobromine, carboxylic acid, N-alkylamine, and hydroxyl
groups. Clopidogrel and risperidone, two pharmaceuticals containing these groups, also showed
moderately high (60%) to very high (95%) deuterium incorporation24. However, some
compounds, such as the drug donepezil which is used to treat Alzheimer's, required up to 12
hours to reach 90% incorporation24.

Conclusion
The addition of deuterium in pharmaceutical compounds has multiple different effects
ranging from a decrease in the rate of metabolism to an increase in stability of a chiral
compound. This in turn allows medicinal chemists to develop new drugs or breathe new life back
into previously patented drugs, both increasing its effectiveness and decreasing the negative side
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effects. While some may have concerns regarding the patentability, toxicity, or cost of these
compounds, these worries do not currently serve as a strong enough deterrent to persuade people
to not study the effects of deuterium incorporation. Deuterium appears to be creating a new wave
in the drug development industry, with multiple experts predicting a similar level of
incorporations of deuterium across the field as the addition of fluorine that occurred years ago.
To this end, new methods for adding deuterium to compounds, especially medically
relevant compounds, are being developed. The majority of these developments focus on
photocatalytic deuterium addition due to its mild reaction conditions which allow for the
persistence of sensitive functional groups. Of these reactions, most proceed through a radical
pathway and involve nanoparticles or nanosheets of previously well known and utilized catalysts
such as ruthenium. Through the utilization of these new reaction conditions, amines, aldehydes,
and aryl groups are able to be deuterated, facilitating the development of deuterated drugs.
Research in this field will only increase as the deuterated drugs already undergoing
clinical trials become approved and more begin to be created. Further research on methods of
activating and deuterating C(sp2)-H bonds is needed and may follow the example of Liu, Yifu,
and Dong and their application of porous CdSe nanosheets. However, even this method is not
perfect as it requires that the desired drug have an acceptable, halogenated intermediate.
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Appendix A
Drug Name

Therapeutic
Indication

Effect of Deuterium

Deutetrabenazine
(Austedo)

Chorea from
Huntingtons

different ratio
metabolites, longer half
life

No

*

JNJ38877605

C-Met inhibitor
(neoplasms)

less toxic, less doses

No

1

Terminated
(Health Risks)

CC-122

melanoma

stabilize enantiomer
switching

No

2

Recruiting

renal insufficiency

No

1

Unknown

lymphoma, nonhodgkin

No

1

Active, Not
Recruiting

lymphoma, nonhodgkin

No

1

Active, Not
Recruiting

diffuse B-cell
lymphoma

No

1

Active, Not
Recruiting

leukemia,
lymphocytic,
chronic B-cell

No

1,2

Completed

lymphoma (nonhodgkin),
lymphoma (large
B-Cell, diffuse),
lymphoma
(follicular)

No

1,2

Recruiting

multiple
myeloma,
lymphoma,
pleiotropic
pathway modifier,
glioblastoma,

No

1

Active, Not
Recruiting

carcinoma,
hepatocellular

No

1

Terminated (No
Health Risk)

carcinoma,
hepatocellular

No

1,2

Unknown

De novo? Phase

Status
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HC-1119

prostate cancer
metastatic,
castrationresistant prostate
cancer

No

3

Not Yet
Recruiting

No

3

Recruiting

No

2

Recruiting

No

3

Recruiting

No

3

Recruiting

Infantile
neuroaxonal
dystrophy

No

2,3

Active, Not
Recruiting

lateral canthal
lines, crows feet,
facial wrinkles

No

2

Completed

autoimmune
(inhibit tyrosine
kinase 2) (with
rosuvastati)

Yes

1

Completed

lupus

Yes

2

Recruiting

ulcerative colitis

Yes

2

Recruiting

less toxic

metastatic
castration
resistant prostate
cancer

ALK-001

stargardt disease,
stargardt macular
degeneration,
stargardt macular
dystrophy,
autosomal
recessive
stargardt disease
1

inhibitor

geographic
atrophy, age
related macular
degeneration,
AMD
RT-001

BMS-986165

Friedreich's
Ataxia, lipid
peroxidation

half life

Martinez 24
granulomatous
colitis, crohn's
disease, crohn's
enteritis,
granulomatous
enteritis

Yes

2

Recruiting

renal impairment

Yes

1

Completed

active psoriatic
arthritis

Yes

2

Active, Not
Recruiting

psoriasis

Yes

3

Recruiting

CTP-543

JAK1 inhibitor,
Alopecia areata

No

3

Recruiting

CTP-656

cystic fibrosis

half life

No

2

Completed

SD-1007 (D3-LDOPA)

Parkinsons

Slows metabolism by
slowing AO metabolism

No

AVP-786

neurobehavioral
disinhibition
(agitation due to
brain injury)

simplify

No

2

Recruiting

schizophrenia

No

2,3

Recruiting

agitation in
patients with
dementia of the
alzheimer's type

No

3

Completed

intermittent
explosive
disorder

No

2

Terminated (No
Health Risk)

depressive
disorder,
treatmentresistant

No

2

Completed

1

Completed

HC-1144

Anti tumor

side effects, half life

No

VX-984

cancer
(endometrial)

reduce aldehyde-oxidase
(AO) metabolism

Yes
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CTP-354

multiple sclerosis
(MS), cerebral
palsy,
improved
amyotrophic
pharmacokinetics
lateral sclerosis (bonding affinity, subunit
specificity,
(ALS), spinal cord
pharmacological activity
injury, and
hereditary
paraplegia

2

Unknown

CTP-518

HIV

No

1

Completed

JZP-386

narcolepsy,
excessive
daytime
sleepiness

No

1

Completed

No

1

Completed

CTP-499

moderate chronic
kidney disease,
non dialysis

No

1

Completed

donafenib

thyroid cancer

No

3

recruiting

metastatic
colorectal cancer

No

3

Completed

advanced
hepatocellular
carcinoma

No

1,2

Not Yet
Recruiting

advanced
gastrointestinal
tumors

No

1,2

Not Yet
Recruiting

nasopharyngeal
carincoma

No

1,2

Recruiting

non-small cell
lung cancer

No

1

Recruiting

hcc

No

2,3

Completed

advanced solid
tumor

No

1,2

Not Yet
Recruiting

No

2

Not Yet
Recruiting

No

2

Not Yet
Recruiting

CTP-730

PXL065 (DRX065)

nonalcoholic
steatohepatitis

CTP-692

schizophrenia

chiral switching

* Indicates that the drug has been approved by the FDA
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